source
- FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravisThe Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…
- Merck partners with Isomorphic Labs to use AI for discovering oncology drug candidatesMerck announced a research collaboration with Isomorphic Labs, an artificial‑intelligence drug design firm, to explore small‑molecule candidates aimed at an undisclosed oncology target. Isomorphic…